文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 基础医学 > In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic
侵权投诉

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model a pre-clinical study

GSK678361 from the very rst day of disease joints with severe changes was 8% for (Fig. 5d). The percentage of animals treated from day 1 of arthritis, compared with 13% for animals treated from day 14. In contrast, untreated or vehicle-treated mice showed 75% and 67% data are illustrated in Fig. 5f.

severely affected joints. These Differential effects of GW856553X on HUVEC responses

To action of GW856553X study the potential mechanism of termined the effect of this inhibitor in a in vivo, we de-panel of assays. In order to determine the effects in vitro endothelial cell-based of GW856553X on endothelial in am-matory responses, HUVEC were stimu-lated presence of 100nM GW856553X. The with TNF-α, in the absence or release after 24 hours of cytokines and chemokines MCP-1) (namely IL-8, IL-6, and modest but consistent (and statistically was measured. We observed signi cant) lease (Figs. 6a-c). However, inhibition inhibition of cytokine re-was 37% for IL-6, 41% for IL-8 in Figs. 6a-less than 50% (24% for MCP-1, c). Addition of higher concentrations of GW856553X inhibition rable modest inhibitory effect was seen (data did not not shown). A result in compa-further when (data IL-1β was used as a stimulus tions, HUVEC viability, assessed using not shown). Under these condi-MTT, was unaffected (data not shown).VEGF, vivoa key gration , was used to promote HUVEC mi-angiogenic stimulus in membrane across an 8μGW856553X did not affect the chemo-in vitro. However, m polycarbonate 100nM tactic tubule formation by AngioKit (see response (Fig. 6d). In contrast, terials CD31 and Methods), Ma-concentration-dependent expression, was as inhibited assessed by 7).

fashion (Fig. in a Discussion

The characterisation of p38 MAPK as a key player in in ammation more than 10 years ago has led to the development of the treatment of in ammatory autoim-several p38 MAPK inhibitors for mune MAPK diseases. inhibitors Several have synthetic demonstrated

p38 To determine the effect on established disease, mice were treated with either GSK678361 10mg/kg Fig. 5. p38 MAPK inhibition reverses joint destruction in chronic CIA.

daily from day 1 of arthritis, or with vehicle from day 1 followed by 10mg/kg daily GSK678361 from day 14 of arthritis (n=5-7 per group). At the end of the study (day 29), animals were sacri ced and paws were sectioned for histological evaluation. Haematoxylin and eosin sections were scored in a blinded fashion for pannus formation, synovitis, bone and cartilage erosion. Representative sections are shown as 10mg/kg GSK678361 from day 14 of arthritis. (follows: (a) untreated, (b) vehicle-treated, (c) 10mg/kg GSK678361 from day 1 of arthritis (d) animal sacri ced on day 14 of arthritis. (e) Panel shows a paw section from a vehicle-treated erate synovitis with some loss of cartilage; 2=extensive synovial hyperplasia, destruction of cartilage f) Paws were assigned one of three grades: 0=normal; 1=mod-and some bone erosions. Results are mean (± SEM) histological score (metatarsal, tibia-tarsus, proxi-mal interphalangeal and distal interphalangeal joints). Statistical analysis was carried out by 1-way ANOVA versus vehicle-treated mice: ***p<0.001.

protective anti-in ammatory effects in animal models of arthritis, such as CIA inhibitory in mice or adjuvant-induced arthritis in intracellular capacity, regardless of high Lewis rats (17-22). However, none of Two ATP concentrations (23). these BIRB-796 and RWJ-67657, have dem-different p38 MAPK inhibitors, passed early clinical trials for the treat-molecules has yet successfully onstrated ment endotoxin clinical such as RA, because of safety concerns of human autoimmune diseases inhibition of p38 MAPK was shown to challenge ef cacy model in in a human which related decrease LPS-induced cytokine and C-with reactive protein production can bind to both the active and inactive other to kinases. possible These cross-reactivities compounds to in vivo and forms of p38, providing an advantage toms, for example those of sepsis (such reduce LPS-induced clinical symp-over ATP and resulting in a very potent

as increased heart rate, decreased blood pressure, fever, and headache) (24, 25).

182

上一页第7页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email